NOS Life Sciences 

Therapeutics for neurodegenerative diseases based on endogenous neuromodulators & proprietary nano-delivery system.

OWNER

Pablo Inones (See Profile)


Sector

Therapeutics

Stage

Prototyping, preclinical

Country

Spain & USA

Our compound reduces Parkinson's dyskinesia by 48%, enhances movement by 100%, and slows down disease progression by 79%

Most suitable combination for current levodopa- based drugs, presenting a 1-year exit via acquisition or technology tran

Alternatively, as stand-alone product it will not require FDA approval.

Patented formulation, method of elaboration and use for neurodegenerative conditions.

Future applications: Alzheimer's (preventive neuroprotector), Down Syndrome, X-Fragil

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

Under evaluation at least till: 30th of June

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar